KESTRA MEDICAL TECHNOLOGIES (KMTS) Company Report

Kestra Medical Technologies (KMTS) reported Q2 2026 revenue of $22.6 million, a 53% increase over the prior year period, driven by a 54% year-over-year increase in prescriptions.
The company achieved a gross margin of 50.6% in Q2 2026, an 11-point increase year-over-year, marking the eighth consecutive quarter of sequential expansion, and expects to reach 70%+ in the next few years.
KMTS raised its fiscal year 2026 revenue guidance to $91 million, representing 52% growth compared to fiscal year 2025.
Operational highlights include expanding to approximately 100 active sales territories and improving in-network payer coverage to the low 80s percentage of fittings, up from 70% nine months ago.
The ACE-PASS clinical study, the largest real-world prospective WCD study with over 21,000 patients, confirmed the Assure system's safety and effectiveness, reporting a high wear time of 23.1 hours and a low false alarm rate with 94% of patients free from false alarms.

Dec 11, 2025, 9:30 PM

Transcript

Kestra Medical Technologies Announces Strong Q2 Fiscal Year 2026 Results and Raises Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies (KMTS) reported Q2 fiscal year 2026 revenue of $22.6 million, a 53% increase year-over-year, driven by a 54% increase in prescriptions.
The company achieved a gross margin of 50.6% in Q2 2026, an 11-point increase from the prior year, marking the eighth consecutive quarter of sequential gross margin expansion, with a long-term target of 70%+.
KMTS increased its fiscal year 2026 revenue guidance to $91 million, representing 52% growth compared to fiscal year 2025, up from previous guidance of $88 million.
The company's cash and cash equivalents totaled $175.4 million as of October 31, 2025, not including $148 million in net proceeds from a recent public equity offering.
Operational highlights include expanding to approximately 100 active sales territories and improving the in-network patient mix to the low 80s, up from 70% nine months prior. The ACE-PASS study, the largest WCD study to date with over 21,000 patients, demonstrated the Assure system's safety, effectiveness, high wear time, and low false alarm rate.

Dec 11, 2025, 9:30 PM

Transcript

Kestra Medical Technologies Reports Strong Q2 2026 Results and Raises Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q2 fiscal year 2026 revenue of $22.6 million, a 53% increase over the prior year period, driven by a 54% year-over-year increase in prescriptions.
The company's gross margin reached 50.6% in Q2 2026, an 11-point increase year over year and the first time exceeding 50%, with management expecting continued expansion towards 70%+ margins in the coming years.
Kestra Medical Technologies raised its fiscal year 2026 revenue guidance to $91 million, representing 52% growth compared to fiscal year 2025, up from its prior guidance of $88 million.
The company expanded its sales organization to approximately 100 active sales territories and improved its in-network payer mix to the low 80s from 70% at the time of its IPO.
Kestra presented primary results from the ACE-PAS study, the largest real-world prospective WCD study with over 21,000 patients, which demonstrated the ASSURE system's safety, effectiveness, highest wear time, and lowest false alarm rate.

Dec 11, 2025, 9:30 PM

Transcript

Kestra Medical Discusses Positive ASSURE Post-Approval Study Results and Commercial Strategy

KMTS

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Kestra Medical announced positive primary results from its 21,000+ patient ASSURE post-approval study, meeting primary and secondary endpoints, which is expected to enhance its competitive position and potentially inform future clinical practice guidelines for Wearable Cardioverter Defibrillators (WCDs). The ASSURE WCD, FDA-approved in 2021, now has the largest clinical data set for WCDs, strengthening its market share efforts against competitors.
Kestra's commercial strategy involves building a direct-to-cardiology sales force, targeting high-prescribing volumes and high payer coverage areas, and using contract partners for patient fittings to scale the business.
In fiscal 2025, Kestra converted 44% of ASSURE prescriptions into revenue, with a fill rate of 85% and 80% of patients in-network, and expects this conversion rate to reach the high 50s by fiscal year 2028.
Management maintains a philosophy of consistent execution to beat and raise guidance and is on track or ahead of its plan to double its sales rep count from the IPO period.

Nov 11, 2025, 8:20 PM

Transcript

Kestra Medical reports positive Assure WCD post-approval study results

KMTS

Revenue Acceleration/Inflection

New Projects/Investments

Guidance Update

Kestra Medical (KMTS) announced positive primary results from its post-approval study for the Assure wearable cardiac defibrillator (WCD), involving over 21,000 patients, which is expected to enhance competitive positioning and potentially lead to stronger clinical guidelines.
The company highlighted a significant market opportunity, with only about 120,000 of an estimated 850,000 eligible patients currently being served by WCDs.
Kestra's commercial strategy involves building a direct-to-cardiology sales force, with plans to double the sales rep count from approximately 70 reps (at IPO) and a typical six-month ramp to full productivity for new territories.
In fiscal 2025, Kestra converted 44% of Assure prescriptions into revenue, with a goal to increase this to the high 60s by fiscal year 2028.
Management maintains a "beat and raise" philosophy for guidance, driven by strong execution and data-driven predictability.

Nov 11, 2025, 8:20 PM

Transcript

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q1 fiscal 2026 revenue of $19.4 million, a 52% increase compared to the prior year period, driven by a 51% year-over-year increase in prescriptions accepted for the Assure system.
The company achieved a gross margin of 45.7% in Q1 2026, marking the seventh consecutive quarter of expansion, and anticipates continued expansion towards 70% plus gross margins.
Kestra Medical Technologies updated its fiscal year 2026 revenue guidance to $88 million, an increase of 47% compared to fiscal year 2025, up from its previous guidance of $85 million.
The in-network patient mix is now approaching 80%, an increase from 70% at the time of its IPO, which contributed to a conversion rate of approximately 47% in Q1 2026.
Enrollment has concluded for the FDA post-approval study, which is expected to include 24,000 to 25,000 patients and will be presented at the American Heart Association Scientific Sessions in November.

Sep 11, 2025, 8:30 PM

Transcript

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY 2026 Revenue Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q1 2026 revenue of $19.4 million, a 52% increase year-over-year, driven by a 51% increase in prescriptions accepted to 4,200. Gross margin expanded to 45.7%, marking the seventh consecutive quarter of expansion.
The company updated its fiscal year 2026 revenue guidance to $88 million, an increase of 47% compared to fiscal year 2025, up from the prior guidance of $85 million.
Operational improvements include the percentage of fittings for patients with in-network benefits now approaching 80%, up from 70% six months prior, and the conversion rate improving to approximately 47% in Q1 2026 from 40% in the prior year period.
Enrollment has concluded for the FDA post-approval study, which is expected to include 24,000-25,000 patients and will be presented at the American Heart Association Scientific Sessions in November.

Sep 11, 2025, 8:30 PM

Transcript

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY26 Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q1 fiscal 2026 revenue of $19.4 million, representing a 52% increase year-over-year, driven by a 51% year-over-year increase in prescriptions accepted for the Assure system.
Gross margin for Q1 2026 was 45.7%, compared to 32.9% in the prior year period, marking the seventh consecutive quarter of gross margin expansion.
The company updated its fiscal year 2026 revenue guidance to $88 million, an increase of 47% compared to fiscal year 2025, which is up from the prior guidance of $85 million.
Cash and cash equivalents totaled $201.2 million as of July 31, 2025.
Kestra achieved a major clinical milestone with the conclusion of enrollment in its FDA post-approval study, which is expected to include between 24,000 and 25,000 patients and will be presented at the American Heart Association Scientific Sessions in November.

Sep 11, 2025, 8:30 PM

Transcript

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY26 Revenue Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies (KMTS) reported strong Q1 2026 results with revenue growing 52% year-over-year to $19.4 million and accepted prescriptions increasing 51% year-over-year to over 4,200.
The company achieved its seventh consecutive quarter of gross margin expansion, reaching 45.7% in Q1 2026, up from 32.9% in the prior year period, and expects to reach 70% plus gross margins in the future.
KMTS updated its fiscal year 2026 revenue guidance to $88 million, representing a 47% increase compared to fiscal year 2025, up from the prior guidance of $85 million.
The percentage of fittings for patients with in-network benefits is now approaching 80%, up from 70% six months ago, contributing to an improved conversion rate of approximately 47% in Q1 2026.
As of July 31, 2025, cash and cash equivalents totaled $201.2 million.

Sep 11, 2025, 8:30 PM

Transcript

Kestra Medical Technologies Reports Q1 FY26 Results and Raises FY26 Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies, Ltd. reported revenue of $19.4 million for the first quarter of fiscal 2026, which ended July 31, 2025, representing a 52% increase compared to the prior year period.
The company's gross margin expanded to 45.7% in Q1 FY26, up from 32.9% in the prior year period.
Kestra Medical Technologies, Ltd. increased its fiscal year 2026 revenue guidance to $88 million, reflecting 47% growth compared to FY25.
The GAAP net loss and comprehensive loss for Q1 FY26 was $25.8 million.
As of July 31, 2025, cash and cash equivalents totaled $201.2 million.